913 related articles for article (PubMed ID: 29805116)
1. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
2. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A; Seki M; Taniguchi S
J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
[TBL] [Abstract][Full Text] [Related]
3. Elobixibat for the treatment of constipation.
Chedid V; Vijayvargiya P; Camilleri M
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
[TBL] [Abstract][Full Text] [Related]
4. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan.
Nakajima A; Taniguchi S; Kurosu S; Gillberg PG; Mattsson JP; Camilleri M
Neurogastroenterol Motil; 2019 May; 31(5):e13571. PubMed ID: 30793431
[TBL] [Abstract][Full Text] [Related]
6. Elobixibat for the treatment of constipation.
Wong BS; Camilleri M
Expert Opin Investig Drugs; 2013 Feb; 22(2):277-84. PubMed ID: 23215781
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.
Fukudo S; Endo Y; Hongo M; Nakajima A; Abe T; Kobayashi H; Nakata T; Nakajima T; Sameshima K; Kaku K;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):603-613. PubMed ID: 30056028
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE
Ikeda N; Taniguchi S; Seki M
Nihon Yakurigaku Zasshi; 2019; 153(3):129-138. PubMed ID: 30867382
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Di Lorenzo C; Khlevner J; Rodriguez-Araujo G; Xie W; Huh SY; Ando M; Hyams JS; Nurko S; Benninga MA; Simon M; Hewson ME; Saps M
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):238-250. PubMed ID: 38211604
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
[TBL] [Abstract][Full Text] [Related]
11. Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD).
Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Fukae J; Nakamura R; Kurita N; Tsunemi T; Oji Y; Saiki S; Nishioka K; Takeshige-Amano H; Taniguchi D; Ogawa T; Kamo H; Eguchi H; Fuse A; Nakajima A; Kano M; Nakajima S; Yanagisawa N; Hattori N
BMJ Open; 2022 Feb; 12(2):e054129. PubMed ID: 35149566
[TBL] [Abstract][Full Text] [Related]
12. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K
BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162
[TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.
Chey WD; Camilleri M; Chang L; Rikner L; Graffner H
Am J Gastroenterol; 2011 Oct; 106(10):1803-12. PubMed ID: 21606974
[TBL] [Abstract][Full Text] [Related]
14. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.
Miner PB
Expert Opin Pharmacother; 2018 Aug; 19(12):1381-1388. PubMed ID: 30129377
[TBL] [Abstract][Full Text] [Related]
15. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
16. Review article: Elobixibat: a novel treatment for chronic constipation.
Khanna L; Camilleri M
Aliment Pharmacol Ther; 2021 Jan; 53(2):234-242. PubMed ID: 33296518
[TBL] [Abstract][Full Text] [Related]
17. Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study.
Ooba N; Takahashi Y; Nagamura M; Takahashi M; Ushida M; Kawakami E; Kimura M; Sato T; Tokuyoshi J; Miyazaki C; Shimada M
Expert Opin Drug Saf; 2021 Dec; 20(12):1553-1558. PubMed ID: 34281471
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.
Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H
Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606
[TBL] [Abstract][Full Text] [Related]
19. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M
Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
Ovchinsky N; Aumar M; Baker A; Baumann U; Bufler P; Cananzi M; Czubkowski P; Durmaz Ö; Fischer R; Indolfi G; Karnsakul WW; Lacaille F; Lee WS; Maggiore G; Rosenthal P; Ruiz M; Sokal E; Sturm E; van der Woerd W; Verkade HJ; Wehrman A; Clemson C; Yu Q; Ni Q; Ruvido J; Manganaro S; Mattsson JP
Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):632-645. PubMed ID: 38670135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
